Based on the above research background, this study took PAH and CTEPH patients as the research object, and clinically intervened with dapagliflozin to explore the efficacy and safety of SGLT2-i in PAH and CTEPH. The gene discussed is SLC5A2; the disease is chronic thromboembolic pulmonary hypertension.